@article { author = {ElNahass, Yasser H and Badawy, Ragia H and ElRefaey, Fatma A and Nooh, Hend A and Ibrahiem, Dalia and Nader, Heba A and Mahmoud, Hossam K and ElMetnawy, Wafaa H}, title = {IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {21}, number = {3}, pages = {721-725}, year = {2020}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.31557/APJCP.2020.21.3.721}, abstract = {Objective: IDH mutations diversely affect the prognosis of cyogenetically normal acute myeloid leukemia (CN-AML) adult patients. The aim of this study is to assess the frequency of IDH mutations and to evaluate its role in AML prognosis. Methods: We have analyzed IDH1 and 2 mutations using High Resolution Melting curve analysis (HRM) in 70 denovo AML patients. Results: The median age of AML patients is 40 years (16-75). Incidence of IDH mutations is 10/70 (14.3%); 2 (2.9%) IDH1 mutant and 8 (11.4%) IDH2 mutant. Median PB blasts of mutant IDH patients was 67.5% (25-96) vs. 44% (0-98) for wild type (p=0.065). Eight/10 (80%) mutant IDH patients had B.M blasts ≥50% vs. 2/10 (20%) <50% (p<0.001) and were classified as intermediate risk cytogenetics (p=0.020) with wild FLT3-ITD (p=0.001). Ten/10 (100%) mutant IDH patients showed wild NPM1 (p=0.049). Median OS of mutant IDH in the intermediate risk cytogenetics was 1.8 years (0.7-3.1) vs. 3.1 years (1.1-5.5) for wild IDH (p=0.05). Conclusion: IDH mutation is mainly associated with intermediate risk AML and when integrated in this specific subgroup displays a lower survival and can be considered an additional integrated molecular risk marker for AML prognosis.  }, keywords = {AML,normal karyotype,intermediate cytogenetic risk,IDH mutations,Prognosis}, url = {https://journal.waocp.org/article_89002.html}, eprint = {https://journal.waocp.org/article_89002_406ab715b07246c4b1e0bc7f515fe231.pdf} }